Czy to juz przesądzone, ze nie zastosuja leczenia radykalnego i pozostaje tylko paliatywne?
Z dostarczonych przez Ciebie (nader szczątkowych) informacji wynikałoby, ze leczenie, ktore mialo byc radykalne czyli kombinowana radioterapia (EBRT+BT RT) okazalo sie, niestety, nieradykalne, bo zapewne agresywny (Gleason 4+4) rak juz wczesniej rozsial sie via uklad limfatyczny i krwionosny po calym organizmie (zdiagnozowane przerzuty do węzlow chlonnych i kosci). W tej chwili kazda zastosowana terapia bedzie wylącznie paliatywna.
Lulka, jesli mamy cokolwiek doradza potrzebne nam są nastepujące informacje/dokumenty:
- wiek/rocznik Taty
- PSA wyjsciowe (sprzed biopsji oraz poprzednie wyniki jesli Tata wczesniej badal PSA)
- opis histopatologii pobiopsyjnej (wklej dokument minus dane osobowe)
- informacyjna karta szpitalna z EBRT+BT (j.w.)
- ewolucja PSA
po radioterapii (z datami)
- opisy wykonanych do tej pory badan obrazowych - scyntygrafia/TK/MRI/PET-CT, etc. (wklej kopie dokumentow)
- nazwy i dawki lekow:
> HT (podaj datę wprowadzenia oraz daty ew. zmian)
> p/bolowych (daty j.w.)
> innych (daty j.w.)
- ostatnie wyniki badan laboratoryjnych (wklej dokument)
Ponizej masz artykul na temat anemii u męzczyzn z zaawansowanym rakiem prostaty.
Prawdopodobne przyczyny anemii u Twojego Taty, to:
- dlugotrwale stosowanie HT (3 lata) - testosteron (czy wiadomo jaki poziom T ma Tata?) jest potrzebny do produkcji erytropoetyny w nerkach
- przerzuty raka do kosci - komorki rakowe zastępują szpik (byc moze nalezaloby zrobic biopsję szpiku?) powodując anemie (niedokrwistość) leukoerytroblastyczną
- obecnosc prozapalnych cytokin produkowanych przez komorki raka prostaty, ktore zmniejszają produkcję erytropoetyny, co z kolei powoduje tzw. niedokrwistość chorób przewlekłych
Oraz (byc moze)
- krwawienia (z pecherza? przewodu pokarmowego? - nic na ten temat nie pisałaś)
- słabe odzywianie (brak apetytu?)
Piszesz, ze Tacie zrobiono w szpitalu badania i przepisano antybiotyk, po ktorym poziom hemoglobiny znacznie wzrósl, co oznaczaloby, ze zostal zlikwidowany jakis stan zapalny w organizmie.
Dobrze byloby gdybys wkleila szpitalną kartę informacyjną dot. tej ostatniej hospitalizacji - powinna byc w niej epikryza, wyniki badan laboratoryjnych oraz zastosowane leczenie.
pzdr
zosia
Anemia in Men with Advanced Prostate Cancer: Incidence, Etiology, and Treatment
Despite increased public awareness and widespread use of prostate-specific antigen (PSA) screening, adenocarcinoma of the prostate continues to be a major cause of morbidity and mortality for American men. In particular, anemia in patients with advanced prostate cancer causes significant morbidity. Symptoms caused by anemia, such as fatigue, malaise, lethargy, dyspnea, and tachycardia, are prevalent in this population and impede daily activities.1
(...)
Etiology
(...)
Castration is a well-documented cause of anemia, as testosterone is required for the enhancement of erythropoietin formation in the kidney, as well as for the marrow action of erythropoiesis. It has been demonstrated that, after castration, red blood cell mass decreases 10%, red blood cell diameter decreases 40%, and osmotic fragility increases.7
Etiology of Anemia in Men With Advanced Prostate Cancer
=> Androgen deprivation
=> Marrow replacement
=> Radiation therapy
=> Radiopharmaceuticals
=> Chemotherapeutics
=> Anemia of chronic disease
=> Inflammatory cytokines
=> Hematuria
=> Poor nutrition
(...)
Studies have also demonstrated a steep decline in hemoglobin level with total androgen blockade, a common therapy for advanced prostate cancer.2,3
Replacement of normal marrow with cancer cells also contributes to anemia in men with prostate cancer. Anemia caused by bone marrow infiltration, called leukoerythroblastic anemia, is well described in various solid malignancies and causes an impaired hematopoiesis, which is evident on the peripheral blood smear. In a study by Shamdas and colleagues,6 28.6% of men with metastatic prostate cancer were found to have leukoerythroblastic anemia.
Other factors that may directly affect the bone marrow include previous or concurrent therapies, such as local radiation to bone marrow, systemic use of radiopharmaceuticals (strontium-89), systemic chemotherapy, and long-term use of combined androgen blockade.2,9
The production of inflammatory cytokines by prostate cancer may also cause a decrease in erythropoietin production, leading to the anemia of chronic disease.10 This myelosuppressive effect on red blood cell supply is believed to be mediated by moieties such as integrins, collagens, laminin, and other bone-derived proteins.
Hematuria and other sources of slow blood loss can also contribute to anemia in men with advanced prostate cancer. Typically, hematuria is caused by internal growth of the prostate into the urethra or growth of metastatic deposits within the wall of the bladder. Although rarely an acute threat to life, hematuria can cause much stress and frustration for both patients and caregivers. Attempts to manage hematuria in this setting include 3-way Foley catheter irrigation with the installation of agents such as alum, silver nitrate, and formalin. Cystoscopy may be beneficial to visualize and fulgurate the source of bleeding.
Treatment
Although the role of continued hormonal therapy in patients with advanced prostate cancer has been a topic of debate following the results of a retrospective analysis by the Southwest Oncology Group,11 a slight improvement in survival for patients who remained on hormonal therapy was demonstrated in a recent analysis by the Eastern Cooperative Oncology Group.12 However, the possibility of a survival advantage must be weighed against the added threat of the normochromic, normocytic anemia that inevitably results from continued hormonal therapy. For patients with advanced prostate cancer, use of a luteinizing hormone-releasing hormone agonist without a peripheral androgen blocker may be beneficial in limiting anemia caused by complete androgen blockade.1
Because the development of anemia in patients with advanced prostate cancer is gradual, supportive measures can be attempted before transfusions become necessary. For patients who have not been deemed transfusion-dependent, the use of entities such as erythropoietin, iron preparations, and vitamin supplementation may be beneficial, although convincing randomized, prospective studies on this topic are lacking.
Given the effect of androgen deprivation and inflammatory cytokines on endogenous erythropoietin production, recombinant erythropoietin has been studied as a treatment option for men with anemia associated with prostate cancer.
In a pilot study of 9 men with androgen-independent prostate cancer and anemia, recombinant human erythropoietin therapy, at a median dose of 150 U/kg administered subcutaneously 3 times a week, increased hemoglobin concentration by more than 10% in 7 men (78%).13Johansson and colleagues14 also described a benefit with the use of recombinant erythropoietin: namely, a decrease in transfusion requirements and an improvement in quality of life.
Low doses of dexamethasone are also being evaluated for the treatment of anemia related to advanced prostate cancer. An increase in hemoglobin was noted in 65% of patients receiving 0.5 mg to 2.0 mg of dexamethasone daily.15
(...)
Main Points
=> Anemia in men with advanced prostate cancer may be caused by several factors, including androgen deprivation, nutritional decline, bone marrow infiltration, treatment-related toxicity, and the chronic inflammatory state.
=> Castration is a well-documented cause of anemia. Combined androgen blockade, however, has been shown to cause a more substantial decline in erythropoiesis.
=> Replacement of normal marrow with cancer cells contributes to anemia in men with prostate cancer. Anemia caused by bone marrow infiltration, called leukoerythroblastic anemia, is well described in various solid malignancies and causes an impaired hematopoiesis.
=> Hematuria and other sources of slow blood loss can also contribute to anemia in men with advanced prostate cancer. Typically, hematuria is caused by internal growth of the prostate into the urethra or growth of metastatic deposits within the wall of the bladder.
=> For patients with advanced prostate cancer, use of a luteinizing hormone-releasing hormone agonist without a peripheral androgen blocker may be beneficial in limiting anemia caused by complete androgen blockade.
=> In patients with limited bone marrow reserve, blood transfusions may be the only effective treatment of anemia associated with prostate cancer.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1472681/